• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型微管蛋白稳定剂埃坡霉素D的临床前药理学

Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent.

作者信息

Wang Hui, Wang Zhi, Wang Shuyi, Li Mao, Nan Li, Rhie Julie K, Covey Joseph M, Zhang Ruiwen, Hill Donald L

机构信息

Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, Cancer Pharmacology Laboratory, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

出版信息

Cancer Chemother Pharmacol. 2005 Sep;56(3):255-60. doi: 10.1007/s00280-004-0965-0. Epub 2005 May 3.

DOI:10.1007/s00280-004-0965-0
PMID:15868148
Abstract

PURPOSE

To determine, for various species, the pharmacological and biochemical properties of epothilone D (EpoD) that are relevant in establishing an appropriate animal model for further evaluation of this promising antitumor agent.

METHODS

A method involving high-performance liquid chromatography (HPLC) was developed and used to assess the stability and protein binding of EpoD in plasma from various species, its metabolism by various S9 fractions, and its pharmacokinetics in mice.

RESULTS

EpoD was stable in dog and human plasma. In plasma from other species, stability decreased in the order: hamster > mouse > guinea pig > rat. EpoD was highly bound to proteins in dog and human plasma. In an evaluation of S9 fractions from mouse, rat, guinea pig, dog, and human, mouse S9 was most efficient in metabolizing EpoD. Following administration to CD2F1 mice, the initial half-lives for plasma elimination of EpoD were <5 min for an intravenous dose and <20 min for an intraperitoneal dose.

CONCLUSIONS

The species differences in EpoD biostability and metabolism may have implications in assessing its antitumor activity and pharmacologic and toxicologic profiles in humans. Relative to humans, the mouse is not a good model for disposition of EpoD; the dog would be more appropriate.

摘要

目的

针对不同物种,确定埃坡霉素D(EpoD)的药理学和生化特性,这些特性对于建立合适的动物模型以进一步评估这种有前景的抗肿瘤药物具有重要意义。

方法

开发了一种涉及高效液相色谱(HPLC)的方法,并用于评估EpoD在不同物种血浆中的稳定性和蛋白结合情况、其在各种S9组分中的代谢情况以及在小鼠体内的药代动力学。

结果

EpoD在犬和人血浆中稳定。在其他物种的血浆中,稳定性按以下顺序降低:仓鼠>小鼠>豚鼠>大鼠。EpoD与犬和人血浆中的蛋白质高度结合。在对小鼠、大鼠、豚鼠、犬和人的S9组分进行评估时,小鼠S9在代谢EpoD方面效率最高。给CD2F1小鼠给药后,静脉注射剂量的EpoD血浆消除初始半衰期<5分钟,腹腔注射剂量的<20分钟。

结论

EpoD生物稳定性和代谢的物种差异可能对评估其在人体内的抗肿瘤活性、药理学和毒理学特征具有影响。相对于人类,小鼠不是用于EpoD处置的良好模型;犬会更合适。

相似文献

1
Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent.新型微管蛋白稳定剂埃坡霉素D的临床前药理学
Cancer Chemother Pharmacol. 2005 Sep;56(3):255-60. doi: 10.1007/s00280-004-0965-0. Epub 2005 May 3.
2
Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents.2-甲氧基抗霉素A化合物作为新型抗肿瘤药物的临床前药理学研究
Cancer Chemother Pharmacol. 2005 Sep;56(3):291-8. doi: 10.1007/s00280-004-0978-8. Epub 2005 May 10.
3
Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.新型抗肿瘤药物阿法司亭(一种抑制bcr/abl的 tyrphostin类似物)的临床前药理学
Cancer Chemother Pharmacol. 2006 May;57(5):607-14. doi: 10.1007/s00280-005-0094-4. Epub 2005 Dec 6.
4
Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.新型选择性p38α抑制剂6-(4-(2,5-二氟苯基)恶唑-5-基)-3-异丙基-[1,2,4]-三唑并[4,3-a]吡啶的临床前药代动力学与代谢:在临床前物种及人肝微粒体中活性代谢物的鉴定
Biopharm Drug Dispos. 2006 Nov;27(8):371-86. doi: 10.1002/bdd.520.
5
In vitro metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo+ ++[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), in mice, rats, dogs, and humans.新型抗癌药物6-N-甲酰氨基-12,13-二氢-1,11-二羟基-13-(β-D-吡喃葡萄糖基)-5H-吲哚并[2,3-a]吡咯并[3,4-c]咔唑-5,7(6H)-二酮(NB-506)在小鼠、大鼠、犬和人体内的体外代谢
Drug Metab Dispos. 1999 Feb;27(2):213-20.
6
Preclinical pharmacology of the natural marine product dolastatin 10 (NSC 376128).天然海洋产物多拉司他汀10(NSC 376128)的临床前药理学
Drug Metab Dispos. 1994 May-Jun;22(3):428-32.
7
Use of a carboxylesterase inhibitor of phenylmethanesulfonyl fluoride to stabilize epothilone D in rat plasma for a validated UHPLC-MS/MS assay.使用苯甲基磺酰氟的羧酸酯酶抑制剂在大鼠血浆中稳定埃坡霉素D以进行经过验证的超高效液相色谱-串联质谱分析。
J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Oct 15;969:60-8. doi: 10.1016/j.jchromb.2014.08.006. Epub 2014 Aug 12.
8
Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.新型抗癌药物ON 01910.Na的临床前药代动力学及体外活性
Cancer Chemother Pharmacol. 2009 Dec;65(1):177-86. doi: 10.1007/s00280-009-1022-9. Epub 2009 May 24.
9
Preclinical discovery of ixabepilone, a highly active antineoplastic agent.伊沙匹隆(一种高效抗肿瘤药物)的临床前发现。
Cancer Chemother Pharmacol. 2008 Dec;63(1):157-66. doi: 10.1007/s00280-008-0724-8. Epub 2008 Mar 18.
10
Biotransformation of a novel antimitotic agent, I-387, by mouse, rat, dog, monkey, and human liver microsomes and in vivo pharmacokinetics in mice.新型抗有丝分裂药物 I-387 的在鼠、大鼠、犬、猴和人肝微粒体中的生物转化及在小鼠体内的药代动力学研究。
Drug Metab Dispos. 2011 Apr;39(4):636-43. doi: 10.1124/dmd.110.036673. Epub 2011 Jan 13.

引用本文的文献

1
Potential Role of Microtubule Stabilizing Agents in Neurodevelopmental Disorders.微管稳定剂在神经发育障碍中的潜在作用。
Int J Mol Sci. 2017 Jul 26;18(8):1627. doi: 10.3390/ijms18081627.
2
Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent.新型吲哚甲酰胺 ML-970 的临床前药理学研究,一种探索性抗癌药物。
Cancer Chemother Pharmacol. 2012 Jun;69(6):1423-31. doi: 10.1007/s00280-012-1851-9. Epub 2012 Feb 25.
3
The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections.
细胞液泡型三磷酸腺苷酶的质子转移结构域为治疗甲型流感病毒感染提供了一个靶标。
Br J Pharmacol. 2011 Sep;164(2):344-57. doi: 10.1111/j.1476-5381.2011.01346.x.
4
Deletion of the STOP gene, a microtubule stabilizing factor, leads only to discrete cerebral metabolic changes in mice.缺失STOP基因(一种微管稳定因子)只会导致小鼠大脑出现离散的代谢变化。
J Neurosci Res. 2008 Mar;86(4):813-20. doi: 10.1002/jnr.21550.